Publications

1. Tang W, Beckley JT, Zhang J, Song R, Xu Y, Kim S, Quirk MC, Robichaud AJ, Diaz ES, Myers SJ, Doherty JJ, Ackley MA, Traynelis SF, Yuan H. (2023) Novel neuroactive steroids as positive allosteric modulators of NMDA receptors: mechanism, site of action, and rescue pharmacology on GRIN variants associated with neurological conditions. Cell Mol Life Sci. 2023 Jan 16;80(2):42. 

2. Brock S, Laquerriere A, Marguet F, Myers SJ, Yuan H, Baralle D, Vanderhasselt T, Stouffs K, Keymolen K, Kim S, Allen J, Shaulsky G, Chelly J, Marcorelle P, Aziza J, Villard L, Sacaze E, de Wit MCY, Wilke M, Mancini GMS, Hehr U, Lim D, Mansour S, Traynelis SF, Beneteau C, Denis-Musquer M, Jansen AC, Fry AE, Bahi-Buisson N. (2023) Overlapping cortical malformations in patients with pathogenic variants in GRIN1 and GRIN2B. J Med Genet. 2023 Feb;60(2):183-192. 

3. Xie L, McDaniel MJ, Perszyk RE, Kim S, Cappuccio G, Shapiro KA, Muñoz-Cabello B, Sanchez-Lara PA, Grand K, Zhang J, Nocilla KA, Sheikh R, Armengol L, Romano R, Pierson TM, Yuan H, Myers SJ, Traynelis SF. (2023) Functional effects of disease-associated variants reveal that the S1-M1 linker of the NMDA receptor critically controls channel opening. Cell Mol Life Sci. 2023 Mar 31;80(4):110. 

4. Hanson JE, Yuan H, Perszyk RE, Banke TG, Xing H, Tsai MC, Menniti FS, Traynelis SF. (2023) Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Neuropsychopharmacology. 2023 Jun 27. doi: 10.1038/s41386-023-01614-3. 

5. Myers SJ*, Yuan H*, Perszyk RE, Zhang J, Kim S, Nocilla KA, Allen JP, Bain JM, Lemke JR, Lal D, Benke TA, Traynelis SF. (2023) Classification of missense variants in the N-methyl-D-aspartate receptor GRIN gene family as gain- or loss-of-function. Hum Mol Genet. 2023 Jun 27:ddad104. doi: 10.1093/hmg/ddad104. (*co-first author)

6. D'Erasmo MP, Akins NS, Ma P, Jing Y, Swanger SA, Sharma SK, Bartsch PW, Menaldino DS, Arcoria PJ, Bui TT, Pons-Bennaceur A, Le P, Allen JP, Ullman EZ, Nocilla KA, Zhang J, Perszyk RE, Kim S, Acker TM, Taz A, Burton SL, Coe K, Fritzemeier RG, Burnashev N, Yuan H, Liotta DC, Traynelis SF. Development of a Dihydroquinoline-Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N-Methyl-d-aspartate Receptor. ACS Chem Neurosci. 2023 Aug 11. doi: 10.1021/acschemneuro.3c00181. PMID: 37566734.

7. Liu N, Li J, Gao K, Perszyk RE, Zhang J, Wang J, Wu Y, Jenkins A, Yuan H, Traynelis SF, Jiang Y. (2023) De novo CLPTM1 variants with reduced GABAA R current response in patients with epilepsy. Epilepsia. 2023 Aug 14. doi: 10.1111/epi.17746. PMID: 37577761.

8. Song R, Zhang J, Perszyk RE, Camp CR, Tang W, Kannan V, Li J, Xu Y, Chen J, Li Y, Liang SH, Traynelis SF, Yuan H. (2023) Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors. Journal of Neurochemistry, 2023 Aug 30. doi: 10.1111/jnc.15942. PMID: 37649269. 

9. Camp CR, Vlachos A, Klöckner C, Krey I, Banke TG, Shariatzadeh N, Ruggiero SM, Galer P, Park KL, Caccavano A, Kimmel S, Yuan X, Yuan H, Helbig I, Benke TA, Lemke JR, Pelkey KA, McBain CJ, Traynelis SF. (2023) Loss of Grin2a Causes a Transient Delay in the Electrophysiological Maturation of Hippocampal Parvalbumin Interneurons. Communications Biology, 2023 August 29, MS accepted.

1   XiangWei W, Jiang Y, Yuan H (2018) De Novo Mutations and Rare Variants Occurring in NMDA Receptors. Curr Opin in Physoil 2:27–35

2  Fry AE, Fawcett KA, Zelnik N, Yuan H, Thompson B, Shemer-Meiri L, Cushion TD, Mugalaasi H, Sims D, Stoodley N,  Chung SK, Rees MI, Patel CV, Brueton LA, Layet V, Giuliano F, Kerr MP, Banne E, Meiner V, Lerman-Sagie T, Helbig KL, Kofman LH, Knight KM, Chen W, Kanan V, Hu C, Kusumoto H, Zhang J, Swanger SA, Shaulsky GH, Mirzaa GM, Muir AM, Mefford HC, Dobyns WB, Mackenzie AB, Mullins JGL, Lemke JR, Bahi-Buisson N, Traynelis SF, Iago HF, Pilz DT (2018) De novo mutations in GRIN1 cause extensive bilateral polymicrogyria. Brain doi: 10.1093/brain/awx358.

3  Fernández-Marmiesse A, Kusumoto H, Rekarte S, Roca I, Zhang J, Myers SJ, Traynelis SF, Couce Mª L, Gutierrez-Solana L, Yuan H (2018) A novel missense mutation in GRIN2A causes a non-epileptic neurodevelopmental disorder with dystonia. Movement Disorders 2018 Jul;33(6):992-999. doi: 10.1002/mds.27315. Epub 2018 Apr 11.

4  Bhattacharya S, Khatri A, Swanger SA, Schaulsky G, Kusumoto H, Hansen KB, Yuan H, Traynelis SF (2018) Unique pharmacological, functional, and trafficking properties of triheteromeric GluN1/GluN2A/GluN2C NMDARs: GluN2C Seldom See the Surface Alone in Cerebellar Granule Cells. Neuron, 2018 Jul 25;99(2):315-328.e5. doi: 10.1016/j.neuron.2018.06.010. Epub 2018 Jun 28.

5  Wells GA, Yuan H, McDaniel MJ, Kusumoto H, Snyder JP, Liotta DC, Traynelis SF (2018) The GluN2B-Glu413Gly NMDA receptor variant arising from a de novo GRIN2B mutation promotes ligand-unbinding and domain opening. PROTEINS: Structure, Function, and Bioinformatics 2018 Dec;86(12):1265-1276. doi: 10.1002/prot.25595.

6  Regan MC, Zhu Z, Yuan H, Myers SJ, Menaldino DS, Tahirovic YA, Liotta DC, Traynelis SF, Furukawa H (2019) Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors. Nature Communications 2019 Jan 18;10(1):321. doi: 10.1038/s41467-019-08291-1.

7  Fu H, Tang W, Chen Z, Belov VV, Zhang G, Shao T, Zhang X, Yu Q, Rong J, Deng X, Han W, Myers SJ, Giffenig P, Wang L, Josephson L, Shao Y, Davenport AT, Daunais JB, Papisov M, Yuan H, Li Z, Traynelis SF, Liang SH (2019) Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([18F]N2B-0518) for GluN2B Subunit in the Brain. ACS Chem Neurosci. 2019 Feb 27. doi: 10.1021/acschemneuro.8b00591.

8  XiangWei W, Kannan V, Kosobucki GJ, Schulien AJ, Kusumoto H, Achkar C, Lesca G, Nguyen S, Helbig KL, Cuisset JM, Fenger CD, Marjanovic D, Wu Y, Bao X, Dirkx N, Schoonjans AS, Myers SJ, Poduri A,  Elias Aizenman, Traynelis SF, Lemke JR, Yuan H*, and Jiang Y* (2019) Clinical Feature & Molecular Mechanism of GRIN2D-related Developmental and Epileptic Encephalopathy. Brian 142(10):3009-3027. doi: 10.1093/brain/awz232. (*co-corresponding author)

9  Li J, Zhang J, Tang W, Mizu RK, Kusumoto H, XiangWei W, Xu Y, Chen W, Amin JB, Hu C, Kannan V, Lin W, Keller SR, Wilcox, WR, Lemke J, Myers SJ, Swanger SA, Wollmuth LP, Petrovski S, and Traynelis SF*, and Yuan H* (2019)  De Novo NMDAR GRIN Variants in M2 Channel Pore-Forming Domain Associated with Neurological Diseases. Human Mutation 40(12):2393-2413, doi: 10.1002/humu.23895. (*co-corresponding author)

10  Myer SJ, Yuan H, Kang J-Q, Tan FCK, Traynelis SF, Low C-M (2019) Distinct roles of GRIN2A and GRIN2B variants in neurological conditions. F1000Res:  F1000 Faculty Rev-1940. doi: 10.12688/f1000research.18949.1. 

11  Perszyk RE, Swanger SA, Shelley C, Khatri A, Fernandez-Cuervo G, Epplin MP, Zhang J, Le P,  Garnier-Amblard E, Yuan H, Menaldino DS, Liotta DC, Liebeskind LS, Traynelis SF (2020) Biased modulation of a ligand-gated ion channel. Nature Chemical Biology. 16:188–196. https://doi.org/10.1038/s41589-019-0449-5

12  Camp CR and Yuan H (2020) GRIN2D/GluN2D NMDA receptor: Unique features and its contribution to pediatric developmental and epileptic encephalopathy. Eur J Paediatr Neurol. S1090-3798(19)30427-1. doi: 10.1016/j.ejpn.2019.12.007.

13  Piard J, Bereau M, XiangWei W, Wirth T, Amsallem D, Buisson L, Richard P, Liu N,  Xu Y, Myers SJ,  Traynelis SF, ChellyJ, Anheim M, Raynaud M,  Van Maldergem L, and Yuan H (2020) The GRIA3 c.2477G>A variant causes a distinctive phenotype of exaggerated startle reflex, chorea and myoclonus. Movement Disorders  DOI:10.1002/mds.28058.

14  Amador A, Bostick CD, Olson H, Peters J, Camp CR, Krizay D, Chen  W, Han W, Tang W, Kanber A, Kim S, Teoh JJ, Petri S, Paek H, Kim A, Lutz CM, Yang M, Myers SJ,  Bhattacharya S, Yuan H, Goldstein DB, Poduri A, Boland MJ, Traynelis SF, Frankel WN. (2020) Modeling and treating GRIN2A developmental and epileptic encephalopathy in mice. Brain 143(7): 2039–2057, doi: 10.1093/brain/awaa147

15  Zhu Z, Yi F, Epplin MP, Liu D, Summer SL, Mizu R, Shaulsky G, XiangWei W, Tang W, Burger PB, Menaldino DS, Myers SJ, Liotta DC, Hansen KB, Yuan H, Traynelis SF (2020) Negative allosteric modulation of GluN1/GluN3 NMDA receptors. Neuropharmacology. 2020 Oct 1;176:108117. doi: 10.1016/j.neuropharm.2020.108117. Epub 2020 May 7. PMID: 32389749; PMCID: PMC7530031.

16  Tang W, Traynelis SF, and Yuan H (2020) Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders. Neuropharmacology, Volume 177, 15 October 2020, 108247. https://doi.org/10.1016/j.neuropharm.2020.108247

17  Perszyk R, Zheng Z, Banke T, Zhang J, Xie L, McDaniel M, Katzman B, Yuan H, Liotta D, Traynelis SF (2021) The Negative Allosteric Modulator EU1794-4 Reduces Single Channel Conductance and Ca2+ Permeability of GluN1/GluN2A NMDA Receptors. Molecular Pharmacology, May;99(5):399-411. doi: 10.1124/molpharm.120.00021

18   Xu Y, Song R, Chen W, Strong K, Shrey D, Gedela S, Traynelis SF, Zhang G, Yuan H (2021) Recurrent seizure-related GRIN1 variant: Molecular mechanism and targeted therapy. Annals of Clinical and Translational Neurology 2021 Jul; 8(7):1480-1494. doi: 10.1002/acn3.51406. Epub 2021 Jul 6. PMID: 34227748; PMCID: PMC8283169.

19   Zhang J, Tang W, Kim S, Myers SJ, Shaulsky G, Dobyns W, Traynelis SF, Yuan H*, Bozarth X* (2021) A Loss-of-Function De Novo GRIN1 Variant Associated with Severe Myoclonus and Developmental Delay: from Molecular Mechanism to Rescue Pharmacology. Frontier in Genetics, doi: 10.3389/fgene.2021.694312 (*co-corresponding author)

20   Hansen KB, Wollmuth LP, Bowie D, Furukawa H, Menniti FS, Sobolevsky AI, Swanson GT, Swanger SA, Greger IH, Nakagawa T, McBain CJ, Jayaraman V, Low CM, Dell'Acqua ML, Diamond JS, Perszyk RE, Camp CR, Yuan H, Traynelis SF (2021) Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels. Pharmacological Reviews. October, 73:1-200. https://doi.org/10.1124/pharmrev.120.000131

21   Benke TA, Park K, Krey I, Camp CR, Song R, Ramsey A, Yuan H, Traynelis SF, Lemke J (2022) Therapeutic implications of genetic variation in the GRIN gene family encoding the NMDARs. Neuropharmacology. MS in review Benke TA, Park K, Krey I, Camp CR, Song R, Ramsey AJ, Yuan H, Traynelis SF, Lemke J (2022) Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs. Neuropharmacology. 2021 Nov 1;199:108805. doi: 10.1016/j.neuropharm.2021.108805. Epub 2021 Sep 22. PMID: 34560056; PMCID: PMC8525401.

22   Han W, Yuan H, Allen JP, Kim S, Shaulsky GH, Perszyk RE, Traynelis SF, Myers SJ (2022) Opportunities for Precision Treatment of GRIN2A and GRIN2B Gain-of-Function Variants in Triheteromeric N-Methyl-D-Aspartate Receptors. J Pharmacol Exp Ther. 2022 Apr;381(1):54-66. doi: 10.1124/jpet.121.001000. Epub 2022 Feb 2. PMID: 35110392.

1  Yuan H*, Hansen KB, Zhang J, Pierson TM, Markello TC, Fuentes  Fajardo KV, Holloman CM, Golas G, Adams DR, Boerkoel CF,  Gahl WA, and Traynelis SF (2014) Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy. Nature Commun. 5:3251 doi: 10.1038/ncomms4251. (*as corresponding author)

2  Hansen KB, Ogden KK, Yuan H, Traynelis SF (2014) Distinct functional and pharmacological properties of triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron, 5;81(5):1084-96. doi: 10.1016/j.neuron.2014.01.035.

3  Pierson TM, Yuan H, Marsh ED, Fuentes Fajardo KV, Adams DR, Markello TC, Golas G, Simeonov DR, Holloman CM, Tankovic A, Karamchandani MM, Schreiber JM, Mullikin JC, Tifft CJ, Toro C, Boerkoel CF,  Traynelis SF, Gahl WA (2014) GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol. DOI: 10.1002/acn3.39.

4  Adams DR, Yuan H, Holyoak T, Arajsd KH, Hakimif P, Markello TC,  Wolfe LA, Vilboux T, Burton BK, Fuentes Fajardo KV,  Grahameg G, Holloman C, Sincan M, Smith ACM, Wells GA, Huang Y, Vega H, Snyder JP, Golas GA, Tifft CJ, MD, Boerkoel CF, Hanson RW, Traynelis SF, Kerr DS, Gahl WA. (2014) Three Rare Diseases in One Sib Pair: RAI1, PCK1, GRIN2B mutations associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity. Mol Genet Metab. pii: S1096-7192(14)00126-7. doi: 10.1016/j.ymgme.2014.04.001.

5  Yuan H, Myers SJ, Wells G, Nicholson KL, Swanger SA, Lyuboslavsky P, Tahirovic YA, Menaldino DS, Ganesh T, Wilson LJ, Liotta DC, Snyder JP, Traynelis SF (2015) Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects. Neuron 85(6):1305-18.

6  Yuan H, Low CM, Moody OA, Jenkins A, and Traynelis SF (2015) Ionotropic GABA and Glutamate Receptor Mutations and Human Neurological Diseases. Mol. Pharm. 88(1):203-17. doi: 10.1124/mol.115.097998

7  Chen W and Yuan H* (2015) GRIN1 Mutations in Early-Onset Epileptic Encephalopathy. Pediatric Neurology Briefs, 29(6):44. http://dx.doi.org/10.15844/pedneurbriefs-29-6-3.

8  Katzman BM, Perszyk RE, Yuan H, Tahirovic YA, Sotimehin AE, Traynelis SF, Liotta DC (2015)  A novel class of negative allosteric modulators of NMDA receptor function. Bioorg Med Chem Lett 25(23):5583-8.

9  Li D^&, Yuan H^&, Ortiz-Gonzalez XR^&, Marsh ED^&, Tian L, McCormick EM, Kosobucki GJ, Chen W, Schulien AJ, Chiavacci R, Tankovic A, Naase C, Brueckner F, von Stülpnagel-Steinbeis C, Hu C, Kusumoto H, Hedrich UB, Elsen G, Hörtnagel K, Aizenman E, Lemke JR, Hakonarson H, Traynelis SF, Falk MJ (2016) GRIN2D recurrent de novo mutation is an autosomal dominant cause of severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet. 99(4):802-816. doi: 10.1016/j.ajhg.2016.07.013.

10  Hu C, Chen W, Yuan H, Traynelis SF (2016) Human GRIN2B Mutations in neurodevelopmental Disorders. J Pharmacol Sci. 132(2):115-121. doi: 10.1016/j.jphs.2016.10.002.

11  Swanger SA, Chen C, Wells G, Burger PB, Tankovic A, Bhattacharya S, Strong KL, Hu C, Kusumoto H, Zhang J, Adams DR, Millichap JJ, Petrovski S, Traynelis SF,* Yuan H* Mechanistic insight into NMDA receptor dysregulation by disease-associated rare variants in the GluN2A and GluN2B agonist binding domains. Am J Hum Genet. 99(6):1261-1280. doi: 10.1016/j.ajhg.2016.10.002.

12  Ogden KK, Chen C, Swanger SA, McDaniel MJ, Fan LZ, Hu C, Tankovic A, Kusumoto H, Kosobucki GJ, Schulien AJ, Su Z, Pecha J, Bhattacharya S, Cohen AE, Aizenman E, Traynelis SF*, Yuan H* (2017) Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology. PLoS Genet 13(1): e1006536. doi:10.1371/journal.pgen.1006536  

13  Gao K, Tankovic A, Zhang Y, Kusumoto H, Zhang J, Chen W, XiangWei W, Shaulsky GH, Hu C, Traynelis SF, Yuan H*, Jiang Y* (2017) A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia. PLoS One 12(2):e0170818. doi: 10.1371/journal.pone.0170818

14  Chen W, Tankovic A, Burger BB, Kusumoto H, Traynelis SF*, Yuan H* (2017) Functional evaluation of a de novo GRIN2A mutation identified in a patient with profound global developmental delay and refractory epilepsy. Mol Pharmacol 91(4):317-330.

15  Chen W, Shieh C,  Swanger SA, Tankovic A, Au M, Madan-Khetarpa S, Tagliati M, Graham J, Madan-Khetarpal S, Traynelis SF, Yuan H, Pierson TM (2017) GRIN1 mutation associated with intellectual disability alters NMDA receptor trafficking and function. J Hum Genet doi: 10.1038/jhg.2017.19.

16  Liu S, Zhou L, Yuan H, Sanz-Clemente A, Badger J, Lu W, Traynelis SF, Roche KW (2017) C-terminus NMDA receptor missense mutations identified in human disease affect receptor localization and synaptic function. J Neurosci. 37(15):4093-4102

17  Platzer K, Yuan H, Schütz H, Winschel A, Chen W, Hu C, Kusumoto H, Heyne HO, Helbig KL, Tang S, Willing MC, Tinkle BT, Adams DJ, Depienne C, Keren B, Mignot C, Frengen E, Strømme P, Biskup S, Döcker D, Strom TM, Mefford HC, Myers CT, Muir AM, LaCroix A, Sadleir L, Scheffer IE, Brilstra E, van Haelst MM, van der Smagt JJ, Bok LA, Møller RS, Jensen UB, Millichap JJ, Berg AT, Goldberg EM, De Bie I, Fox S, Major P, Jones JR, Zackai EH, Abou Jamra R, Rolfs A, Leventer RJ, Lawson JA, Roscioli T, Jansen FE, Ranza E, Korff CM, Lehesjoki AE, Courage C, Linnankivi T, Smith DR, Stanley C, Mintz M, McKnight D, Decker A, Tan WH, Tarnopolsky MA, Brady LI, Wolff M, Dondit L, Pedro HF, Parisotto SE, Jones KL, Patel AD, Franz DN, Vanzo R, Marco E, Ranells JD, Di Donato N, Dobyns WB, Laube B, Traynelis SF, Lemke JR (2017) GRIN2B encephalopathy – novel findings on phenotype, variant clustering, functional consequences and treatment. J Med Genet 54(7):460-470.

18  Yadav R, Dravid SM, Yuan H, Traynelis SF (2017) AMPA receptors molecular biology, pharmacology. In “The New Encyclopedia of Neuroscience” Eds RS Larry, Elsevier, DOI: 10.1016/B978-0-12-809324-5.02325-7.

1  Yamada K, Ji JJ, Yuan H, Miki T, Sato S, Horimoto N, Shimizu T, Seino S, Inagaki N (2001) Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science 292:1543-46.

2  Yamada K, Yuan H, Inagaki N (2002). Hypoxia-induced generalized seizure and ATP-sensitive potassium channels. Clinical Neuroscience 20: 483 (in Japanese).

3  Yuan H, Yamada K, Inagaki N (2004) Multiminute oscillations in mouse substantia nigra pars reticulata neurons in vitro. Neurosci Lett. 355(3):136-40.

4  Yuan H, Yamada K, Inagaki N (2004) Glucose sensitivity in mouse substantia nigra pars reticulata neurons in vitro. Neurosci Lett. 355(3):173-6.

5  Chen PE, Geballe MT, Stansfeld PJ, Johnston AR, Yuan H, Jacob AL, Snyder JP, Traynelis SF, Wyllie DJ (2005) Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol. 67(5):1470-84.

6  Yuan H*, Erreger K, Dravid SM, Traynelis SF (2005) Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3. J Biol Chem. 280(33):29708-16. (*as corresponding author)

7  Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Almonte A, Murray E, Mosely C, Barber J, French A, Balster R, Murray TF, Traynelis SF (2007) Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol. 581(Pt 1):107-28.

8  Lee CJ, Mannaioni G, Yuan H, Woo DH, Gingrich MB, Traynelis SF (2007) Astrocytic control of synaptic NMDA receptors. J Physiol. 581(Pt 3):1057-81.

9  Hansen KB, Yuan H, Traynelis SF (2007) Structural aspects of AMPA receptor activation, desensitization and deactivation. Curr Opin Neurobiol. 17(3):281-8.

10  Hamill CE, Caudle WM, Richardson JR, Yuan H, Pennell KD, Greene JG, Miller GW, Traynelis SF (2007) Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Mol Pharmacol. 72(3):653-64.

11  Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ, Yuan H, Le P, Lyuboslavsky PN, Micale N, Jørgensen L, Clausen RP, Wyllie DJ, Snyder JP, Traynelis SF (2007) Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol. 72(4):907-20.

12  Dravid SM, Yuan H, Traynelis SF (2007) AMPA receptors molecular biology, pharmacology. In “The New Encyclopedia of Neuroscience” Eds RS Larry, Elsevier, p1-8.

13  Mannaioni G, Yuan H, Lee CJ, Traynelis SF (2008) A starring role for astrocytes. Physiology News. 70:31-33.

14  Mannaioni G, Orr AG, Hamill CE, Yuan H, Pedone KH, McCoy KL, Berlinguer Palmini R, Junge CE, Lee CJ, Yepes M, Hepler JR, Traynelis SF (2008) Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. J Biol Chem. 283(29):20600-11.

15  Tahirovic YA, Geballe M, Gruszecka-Kowalik E, Myers SJ, Lyuboslavsky P, Le P, French A, Irier H, Choi WB, Easterling K, Yuan H, Wilson LJ, Kotloski R, McNamara JO, Dingledine R, Liotta DC, Traynelis SF, Snyder JP (2008) Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem. 51(18):5506-21.

16  Yuan H, Geballe MT, Hansen KB, Traynelis SF (2008) Structure and Function of NMDA receptors. In “Structural and Functional Organization of the Synapse” Eds MD Ehlers and JW Hell, Springer, p289-316.

17  Yuan H, Vance KM, Junge CE, Geballe MT, Snyder JP, Hepler JR, Yepes M, Low CM, Traynelis SF (2009) The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem. 284(19):12862-73.

18  Mosley CA, Myers SJ, Murray EE, Santangelo R, Tahirovic YA, Kurtkaya N, Mullasseril P, Yuan H, Lyuboslavsky P, Le P, Wilson LJ, Yepes M, Dingledine R, Traynelis SF, Liotta DC (2009) Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. Bioorg Med Chem. 17(17):6463-80.

19  Yuan H*, Hansen KB, Vance KM, Ogden K, Traynelis SF (2009) Control of N-methyl-D-aspartate receptor function by the NR2 subunit amino-terminal domain. J Neurosci. 29(39):12045-12058. (*as corresponding author)

20  Hansen KB, Mullasseril P, Dawit S, Kurtkaya NL, Yuan H, Vance KM, Orr AG, Kvist T, Ogden KK, Le P, Vellano KM, Lewis L, Kurtkaya S, Du Y, Qui M, Murphy TJ, Snyder JP, Brauner-Osborne H, Traynelis SF (2010) Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective NMDA receptor antagonists. J Pharmacol Exp Ther. 333(3):650-62. doi: 10.1124/jpet.110.166256.

21  Mullasseril P, Hansen KB, Vance KM, Ogden KK, Yuan H, Kurtkaya NL, Santangelo R, Orr AG, Le P, Vellano KM, Liotta DC, Traynelis SF (2010) A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat Commun. 2010 Oct;1(7):1-8.

22  Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R. (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 62(3):405-96.

23  Acker TM, Yuan H, Hansen KB, Vance KM, Ogden KK, Jensen HS, Burger1 PB, Snyder J, Liotta DC, Traynelis SF (2011) Expanding N-Methyl-D-Aspartate Receptor Pharmacology: A Novel Class of Non-Competitive GluN2C/D Subunit Selective Antagonist. Mol. Pharm.80(5):782-95.

24  Burger PB, Yuan H, Karakas E, Geballe M, Furukawa H, Liotta DC, Snyder JP, Traynelis SF (2012) Mapping the Binding of GluN2B-Selective N-Methyl-D-aspartate Receptor Negative Allosteric Modulators. Mol. Pharm. 82(2):344-59.